TABLE 1.

The clinical characteristics of three patients with Sars‐cov‐2 associated Telogen Effluvium (TE)

	Age (years)	Onset of hair shedding (days from febrile peak)	Febrile peak (°C)	Medical history
Case 1	62	75	39	Autoimmune thrombocytopenia Osteoporosis
Case 2	74	60	39.2	Diabetes mellitus Systemic hypertension Dyslipidemia
Case 3	58	36	39	None
		Clinical findings	Medications during hospitalization
Case 1		Distress respiratory syndrome Bilateral interstitial pneumonia No skin manifestations	Enoxaparin 6000 IU/die Ceftriaxone 1 g 3/die Tocilizumab 400 mg (only 1 day) Lopinavir/ritonavir 400/100 mg 2/die
Case 2		Moderate dyspnea up to distress respiratory syndrome Bilateral interstitial pneumonia No skin manifestations	Gliclazide 60 mg 1/die (home therapy) Acarbose 100 mg 2/die (home therapy) Ezetimibe/simvastatin 10/10 mg 1/die Sitagliptin 50 mg 1/die (home therapy) Enoxaparin 6000 UI 1/die Lopinavir/Ritonavir 400/100 mg 2/die (only 1 day)
Case 3		Bilateral interstitial pneumonia Diarrhea Weight loss (4 Kg) in 2 weeks Diffuse itching and flushing during hospitalization	Enoxaparina 6000 IU/die Lopinavir/Ritonavir 400/100 mg 2/die (only 2 days) chlorphenamine maleate 10 mg 1/die
		Treatment		Diagnosis
Case 1		Oral supplementation with sulfur amino acid/vit B6 Peptide mimicking hair growth factor lotion		Acute TE
Case 2		Oral supplementation with sulfur amino acid/vit B6 Peptide mimicking hair growth factor lotion		Acute TE
Case 3		Minoxidil 5% lotion Peptide mimicking hair growth factor lotion Oral supplementation with sulfur amino acid/vit B6		Acute TE on initial AGA a

^a Androgenetic alopecia (AGA).